Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
about
Better plans and more powerful evidence are needed in the research and treatment of chronic hepatitis B in China.Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapyCost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaRecent advances in micro/nanotechnologies for global control of hepatitis B infectionResistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).Distribution and epidemiologic trends of HBV genotypes and subtypes in 14 countries neighboring chinaThe cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Future prospectives for the management of chronic hepatitis B.Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations.Compensatory variances of drug-induced hepatitis B virus YMDD mutations.Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future.Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients.Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran.Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistanceGenotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B
P2860
Q26765290-7B634017-73AD-4116-BD8D-EF3655888E5AQ28488149-C5004705-D9B1-4E18-A379-18D1665186E1Q28550643-D4DAA481-778E-4EE1-A989-16A2BAF7B228Q30394611-C309607E-44E3-49E7-A5EB-B55A0C19DB3FQ34647599-6E1A00F3-4F93-4A7B-8DFB-53F9694498AAQ34719476-1404033F-4693-45E7-99BD-440BE1DFF13EQ35671668-D6513E92-48AB-44F8-BE80-BCE47A926CC0Q36189795-245C0A1A-0809-4CFB-881D-1F8BFF3013E1Q36841719-A5269661-C96F-4ABA-B10B-5756F349F002Q36975077-7FEFA776-9564-43F7-8AB2-D3261A0D52EFQ37181728-94D2B4DF-5128-4DFB-A76B-479B62CB54B7Q37754603-3011DC33-D7DE-467C-96F9-DE4A81C8FF6EQ40197893-6025B95E-F5BB-4501-B71C-3FC8F4E9BCEBQ40236925-7BB468D3-FEB0-4D77-B5EC-397F563F4C8AQ40493686-0E9E3C18-8DBB-400F-96F0-E54F54B7547FQ42955628-62672A7B-4EED-45AA-9506-CFAC70EF9E4CQ43243611-D15CF4AA-6A9B-437C-9FE9-3F5A22D1FBB6Q56895288-4CDDC225-70CA-4C70-B8A2-E3F75265463AQ58690974-49E2C113-AC1B-42AD-B0BE-7B048D383BC9
P2860
Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Response to long-term lamivudi ...... genotype and drug resistance.
@ast
Response to long-term lamivudi ...... genotype and drug resistance.
@en
type
label
Response to long-term lamivudi ...... genotype and drug resistance.
@ast
Response to long-term lamivudi ...... genotype and drug resistance.
@en
prefLabel
Response to long-term lamivudi ...... genotype and drug resistance.
@ast
Response to long-term lamivudi ...... genotype and drug resistance.
@en
P2093
P2860
P1476
Response to long-term lamivudi ...... f genotype and drug resistance
@en
P2093
Heathcote EJ
Moskovitz DN
P2860
P304
P356
10.1111/J.1365-2893.2005.00613.X
P577
2005-07-01T00:00:00Z